MAFLD
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: (1) Diagnostic criteria based on the international expert consensus profile of the new definition of MASLD (2) MRI-PDFF showed steatosis =8% (3) Age 18-80 years old
Exclusion criteria
Exclusion criteria: (1) Viral hepatitis, Wilson's disease, autoimmune liver disease, drug-induced liver disease and other specific liver diseases that can lead to fatty liver or abnormal liver function (2) Patients with advanced liver cirrhosis, liver cancer and other tumors (3) Patients with lower extremity vascular diseases such as varicose veins of the lower limbs, deep vein thrombosis of the lower extremities (more than 2 points on the Caprini score scale), arterial stenosis of the lower extremities (with symptoms such as intermittent claudication and decreased skin temperature). (4) Patients with fractures or joint strains and sprains within half a year (5) Uncontrolled cardiovascular and cerebrovascular diseases (6) In pregnancy (7) Patients who are on antiviral and anti-tuberculosis therapy (8) Poor blood sugar control (9) Patients with absolute and relative contraindications to cardiopulmonary stress testing ( Absolute contraindications, including: a) Acute myocardial infarction within 2 days; b) unstable angina; c) uncontrolled cardiac arrhythmias, accompanied by symptoms or hemodynamic instability; d) symptomatic severe coarctation of the aorta; e) decompensated heart failure; f) Acute pulmonary embolism; g) acute deep vein thrombosis; h) Acute myocarditis; i) Acute pericarditis; j) Acute aortic dissection; k) Persons with disabilities who pose a safety hazard; l) Psychiatric illness that is unable to communicate. Relative contraindications, including: a) left coronary artery main stenosis; b) valvular heart disease with moderate stenosis; c) electrolyte imbalances; d) elevated blood pressure (resting systolic blood pressure >200 mmHg or diastolic blood pressure > 110 mmHg or both); e) tachycardia; f) bradycardia; g) High-grade atrioventricular block; h) Severe hypertrophic obstructive cardiomyopathy; i) Those who are unable to cooperate with the examination. )
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| proton Density Fat Fraction; | — |
Secondary
| Measure | Time frame |
|---|---|
| magnetic resonance elastography;Alanine aminotransferase;Aspartate aminotransferase; | — |
Countries
China
Contacts
Friendship Hospital Affiliated to Capital Medical University